[New opportunities in the treatment of patients with multiple sclerosis (Resolution of the Council of Experts on April 23, 2022, Moscow, JSC «BIOCAD»)].

N N Spirin,Ya V Vlasov,M N Zakharova,N V Khachanova,E V Popova,F A Khabirov,N A Totolyan,S A Sivertseva,Z A Goncharova,L L Korsunskaya, T I Yakushina, O V Matvievskaya,T O Simaniv,A N Boyko

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova（2022）

引用 3|浏览5

暂无评分

摘要

One of the target areas for the development of the Russian pharmaceutical industry at present is the development of next-in-class drugs medicines. These are original, patent-protected drugs that act on known biological targets, improved or modified in structure and mechanism of action compared to existing, successfully proven medicine. The article presents the results of an expert council on the management of patients with multiple sclerosis and the place of new original medicines of the JSC BIOCAD company (SamPEG-IFN-β1a and divozilimab) in multiple sclerosis therapy algorithm.

查看译文

关键词

SamPEG-IFN-β1a,divozilimab,multiple sclerosis,next-in-class medicine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要